[Pathophysiology of chemotherapy-associated thrombosis].
Epidemiological studies revealed that most antineoplastic agents and regimes enhance the risk of venous and arterial thromboembolic events in cancer patients. The purpose of this article is to review clinical and pathophysiological data related to chemotherapy-associated thromboembolism under special consideration of newer treatment strategies, such as angiogenesis inhibitors and immunmodulatory agents. Despite numerous clinical and experimental studies it has to be concluded that we are far from a comprehensive understanding of the pathogenesis of chemotherapy-associated thrombosis.
Lechner
D
D
Abteilung für Hämatologie und Hämostaseologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Osterreich. daniel.lechner@meduniwien.ac.at
Weltermann
A
A
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000964:Antimetabolites, Antineoplastic / Q000633:toxicity; D000970:Antineoplastic Agents / Q000633:toxicity*; D002945:Cisplatin / Q000633:toxicity; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D020521:Stroke / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D013927:Thrombosis / Q000139:chemically induced* / Q000503:physiopathology* / Q000517:prevention & control
D020533:Angiogenesis Inhibitors; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002945:Cisplatin